Efficacy of Tolvaptan in heart failure patients with preserved Ejection fraction: multicenter, RaNdomized, open-label triAL (ETERNAL)

Trial Profile

Efficacy of Tolvaptan in heart failure patients with preserved Ejection fraction: multicenter, RaNdomized, open-label triAL (ETERNAL)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Jul 2018

At a glance

  • Drugs Tolvaptan (Primary)
  • Indications Heart failure
  • Focus Biomarker; Pharmacodynamics
  • Acronyms ETERNAL
  • Most Recent Events

    • 02 Jul 2018 Status changed from recruiting to active, no longer recruiting.
    • 06 Jul 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top